The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...
LGBTQ Nation on MSN10h
Once-a-year shot for HIV protection passes early safety trialAn annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Clinical Trials Arena on MSN16h
MSD to push for approval of HIV combo after Phase III successMSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.
Children exposed to antiretroviral (ARV) therapy in utero and not exposed to HIV showed no difference in language development at 5 years of age compared with unexposed children, based on new data from ...
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 ...
Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback